XT
KROS icon

XTX Topco’s Keros Therapeutics KROS Stock Holding History

XTX Topco’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$975K Buy
88,322
+77,898
+747% +$1.2M 0.02% 1439
2025
Q4 		$212K Buy
+10,424
New +$183K 0.01% 2358
2025
Q3 		– Sell
-54,145
Closed -$723K – 2927
2025
Q2 		$723K Buy
54,145
+6,024
+13% +$81.3K 0.03% 859
2025
Q1 		$490K Buy
+48,121
New +$559K 0.03% 1048
2024
Q3 		– Sell
-4,996
Closed -$228K – 2353
2024
Q2 		$228K Buy
+4,996
New +$268K 0.02% 1147

Other funds holding KROS

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return